Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic ...

The new MG HS brings a bold new vision to the segment, building further on its international success. It is an exceptional mid-size SUV that redefines style, performance and technology in the sector.

Patients with castrate testosterone levels were randomized to receive TALZENNA 0.5 mg/day plus XTANDI ... TALZENNA in combination with XTANDI is now approved in more than 40 countries globally ...

Patients with castrate testosterone levels were randomized to receive TALZENNA 0.5 mg/day plus ... use with XTANDI for patients with mCRPC, with or without gene mutations. TALZENNA in combination with ...

Remember the Mini? And its designer, Alec Issigonis? That sort of brings us to the MG’s quite brilliant Midget, which, like all MGs, was built around the inexpensive mechanical aggregates of a ...

Patients in both cohorts were randomly assigned 1:1 to receive enzalutamide (160 mg daily) combined with either talazoparib (0.5 mg daily) or placebo. Overall survival data in the unselected ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...